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Abstract
Background: Home ultraviolet B (UVB) treatment is a much-debated treatment, especially with regard to
effectiveness, safety and side effects. However, it is increasingly being prescribed, especially in the Netherlands.
Despite ongoing discussions, no randomised research has been performed, and only two studies actually compare
two groups of patients. Thus, firm evidence to support or discourage the use of home UVB phototherapy has not
yet been obtained. This is the goal of the present study, the PLUTO study (Dutch acronym for "national trial on
home UVB phototherapy for psoriasis").
Methods: We designed a pragmatic randomised single-blind multi-centre trial. This trial is designed to evaluate
the impact of home UVB treatment versus UVB phototherapy in a hospital outpatient clinic as to effectiveness,
quality of life and cost-effectiveness. In total 196 patients with psoriasis who were clinically eligible for UVB
phototherapy were included. Normally 85% of the patients treated with UVB show a relevant clinical response.
With a power of 80% and a 0.05 significance level it will be possible to detect a reduction in effectiveness of 15%.
Effectiveness will be determined by calculating differences in the Psoriasis Area and Severity Index (PASI) and the
Self Administered PASI (SAPASI) scores. Quality of life is measured using several validated generic questionnaires
and a disease-specific questionnaire. Other outcome measures include costs, side effects, dosimetry, concomitant
use of medication and patient satisfaction. Patients are followed throughout the therapy and for 12 months
thereafter. The study is no longer recruiting patients, and is expected to report in 2006.
Discussion: In the field of home UVB phototherapy this trial is the first randomised parallel group study. As such,
this trial addresses the weaknesses encountered in previous studies. The pragmatic design ensures that the results
can be well generalised to the target population. Because, in addition to effectiveness, aspects such as quality of
life and cost-effectiveness are also taken into consideration, this study will produce valuable evidence to either
support or discourage prescription of home UVB phototherapy.
Trial registration: Current controlled trials/Nederlands Trial register: ISRCTN83025173. Clinicaltrials.gov:
NCT00150930
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Background
About 2% to 4% of the Dutch population suffer from pso-
riasis. Psoriasis is a chronic recurrent skin disorder charac-
terised by erythematosquamous lesions (plaques).
Usually the affected areas are few, but occasionaly the dis-
ease is more generalised. Psoriasis can be treated topically
by application of creams and ointments, for instance cor-
ticosteroids and vitamin D3. For most patients topical
therapy will suffice. However, for some patients the area
involved is so extensive that local treatment is not feasible.
In other cases the skin lesions no longer respond to topi-
cal treatment. In that case the dermatologist may start irra-
diation with ultraviolet (UV) light or prescribe systemic
medication. UV irradiation of the skin can be performed
with different types of UV light: e.g. UVA, broadband
UVB, or narrowband UVB. UVB irradiation is usually pre-
scribed as a single therapy. However, adjuvant use of top-
ical therapy may be continued.
UVB therapy has considerable consequences for the
patient because it is nearly always carried out in a hospital
outpatient clinic. The UVB irradiation itself normally
takes only a few minutes, but to receive the irradiation
patients have to travel to the outpatient department dur-
ing working hours two to three times a week. In general it
is a relatively time-consuming treatment. For hospital per-
sonnel as well, this mode of therapy demands a consider-
able investment of time. They have to determine the
dosage, set the machine to the proper dosage, and fill out
the medical records for each patient visit.
To overcome the drawbacks of UVB treatment in the out-
patient clinic, home UVB phototherapy was introduced
over 25 years ago [1-4]. Ever since, however, the safety and
effectiveness of home UVB have been the subject of
debate [5-13]. Despite all discussion, increasing numbers
of dermatologists seem to be prescribing home UVB pho-
totherapy to their patients.
In an earlier study we listed all known publications and
studies on home UVB phototherapy, and conducted a sur-
vey among dermatologists [14]. We found that in the
Netherlands home UVB is currently prescribed to approx-
imately 5% of the UVB-treated patients, with some derma-
tologists prescribing it in 100% of the cases. We also
demonstrated that there is no firm evidence that would
either support or dissuade from prescribing home UVB
phototherapy. Glaringly absent is any randomised
research in this area. This lack of research has resulted in
ongoing discussions and the dissemination of personal,
non-evidence based opinions, especially with regard to
issues like effectiveness, side effects and cost [14]. Thus, in
general, home UVB phototherapy remains a debated treat-
ment. We concluded that only randomised research on
home UVB phototherapy as compared to UVB treatment
in an outpatient setting could resolve the issue [14].
In this paper, we describe a randomised pragmatic trial
that we are currently conducting, a national trial on home
UVB phototherapy for psoriasis. The Dutch acronym for
this trial is PLUTO (Psoriasis: Landelijk UVB Thuisbelich-
tings Onderzoek). The trial is designed to evaluate the
impact of home UVB phototherapy versus conventional
outpatient UVB phototherapy on effectiveness, quality of
life and cost-effectiveness. The focus is on narrowband
UVB treatment (TL-01 lamps). The study tests the hypoth-
esis that home UVB phototherapy is as effective as outpa-
tient UVB phototherapy. We further expect a better quality
of life when patients are treated at home, and we hypoth-
esize that home treatment will have similar or reduced
total costs. This article presents the design of this trial.
Methods
Objective
The aim of this study is to compare home UVB (TL-01)
phototherapy with the current outpatient UVB (TL-01)
phototherapy for patients with psoriasis. This objective
was specified by the following research questions. Com-
pared to outpatient UVB phototherapy:
1. Is home UVB phototherapy for patients with psoriasis
equally effective?
2. Does home UVB phototherapy yield a better quality of
life?
3. Are costs for home UVB phototherapy higher, lower or
similar?
4. Is home UVB phototherapy cost-effective?
Design
We conducted a pragmatic randomised parallel group sin-
gle-blind multi-centre trial among psoriasis patients eligi-
ble for narrowband UVB (TL-01) phototherapy. Patients
were randomly allocated to two groups, thus obtaining
two treatment groups of equivalent prognosis. One group
was given home UVB phototherapy and the other UVB
phototherapy in the outpatient department of the partici-
pating hospitals.
The design was chosen to be 'pragmatic' in order to com-
pare the two treatments under the conditions in which
they would be applied in daily practice [15]. Accordingly,
in our pragmatic trial we randomised the patients into
two treatment groups, but we did not impose a prespeci-
fied treatment regimen on the participants. Instead, we
urged dermatologists to carry out the assigned UVB treat-
ments as they would normally, and thus to act in accord-BMC Medical Research Methodology 2006, 6:39 http://www.biomedcentral.com/1471-2288/6/39
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ance with their own views. Consequently, all of the
implicit differences in the two treatments were compared,
including factors such as frequency of irradiations, dos-
age, compliance, concomitant medication, support and
equipment. We did not control for these and other possi-
ble differences relating to the treatment, because they can-
not be controlled for in a real life situation.
The locations of the two treatments (at home versus in the
outpatient department) of course made blinding of the
participants impossible. Because of the pragmatic design
of the study it was not desirable to blind the dermatolo-
gist. However, we arranged for the extent and severity of
the psoriasis to be assessed by an independant research
nurse blinded to treatment form.
Study population
Psoriasis patients who were clinically eligible for narrow-
band UVB (TL-01) phototherapy ànd who had had this
therapy prescribed by their own dermatologist were
invited to participate in the study. All inclusion and exclu-
sion criteria are displayed in table 1.
The main selection criterion of being "clinically eligible
for narrowband UVB treatment" was purely pragmatic
and was left to the discretion of the participating derma-
tologist. However, dermatologists were explicitly discour-
aged from increasing the number of their prescriptions on
behalf of the study. No financial benefit or other compen-
sation was offered to participating dermatologists for their
efforts; this to avoid any conflict of interest and to include
only those patients who would otherwise have received
narrowband UVB treatment. Likewise, the patients also
received no material compensation for their participation
in the study.
Sample size
The sample size could not be calculated on the basis of
presumed differences in effectiveness as there is no clear
data available on the possible differences in treatment
effects. However, based on the data available from a 1993
pilot study [16] and recent experience with home UVB
phototherapy, we in fact expected the effectiveness of
both therapies to be similar. The sample size was therefore
calculated in accordance with a negative trial approach
[17]. We considered a 50% or greater improvement in the
psoriasis severity from baseline to be a relevant clinical
response. A systematic review by Spuls et al. indicates that
approximately 85% of the patients treated with UVB show
at least a 50% improvement in their psoriasis [18]. Thus,
with N = 90 per per treatment group and at α = 0.05 and
β = 0.20 (power 80%), we would be able to show a differ-
ence in effectiveness of 15% or more; i.e., a reduction in
effectiveness from 85% to 70% or less should be distin-
guishable. To allow for missing data and losses to follow-
up (i.e. withdrawals, incomplete case register forms) we
aimed at 100 patients per group, 200 in total. To obtain
accurate estimates of the cumulative costs of UVB treat-
ment a consecutive sample of 100 patients (50 per group)
was considered to be sufficient, because little variation
Table 1: Eligibility criteria. Study participants were subject to the following inclusion and exclusion criteria.
Inclusion criteria:
1. Guttate or plaque psoriasis, clinically eligible for narrowband UVB (TL-01) phototherapy;
2. Willing to undergo treatment according to randomisation.
Exclusion criteria:
1. No informed consent:
• age below 18 years;
• not willing to accept one of the two treatments offered;
2. Practical reasons:
• not able to receive one of the two treatments offered (e.g. lack of space at home/living too far from hospital etc.);
• analphabetism (unable to read the patient information and the questionnaires, unable to provide written answers and written informed 
consent);
• lack of command of the Dutch language;
• not in possession of a telephone.
3. Expected non-compliance:
lack of understanding of what the study/treatment is about, and its potential consequences.
4. Medical contraindications:
• Malignancy of the skin in the past/at present;
• known UVB-allergy or chronic polymorphic photodermatosis;
• use (at time of inclusion) of medication with known phototoxic or photoallergic properties;
• use (at time of inclusion) of systemic antipsoriatic medication (cyclosporin, methotrexate, neotigason, fumaric acid);
• history of exposure to ionising radiation.BMC Medical Research Methodology 2006, 6:39 http://www.biomedcentral.com/1471-2288/6/39
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was expected in treatment duration, number of UVB irra-
diations, and use of concomitant medication.
Recruitment
Hospitals
We planned to include two hundred patients in approxi-
mately 2 years' time, starting October 2002. To achieve
this, several hospitals were invited to join the study. Ini-
tially five university hospitals and one closely related non-
university hospital agreed to participate. Later on, when
inclusion of patients fell short of expectations, another
eight hospitals were recruited from the same districts or
nearby. In total 14 hospitals took part in the trial; 5 uni-
versity hospitals and 9 non-university hospitals.
Patients
When the dermatologists of the collaborating hospitals
prescribed UVB phototherapy to a patient, they checked
eligibility for the trial using the above-mentioned list of
inclusion and exclusion criteria (table 1). If all criteria
were met, patients were informed about the possibility of
participating. If the patient was interested, he/she received
written information to take home. The same day the cen-
tral coordination centre (UMC Utrecht) was provided
with the name and phone number of the patient.
After 1–2 days the investigators at the central coordina-
tion centre contacted the patient by telephone and pro-
vided additional information. During this conversation
the principle of randomisation (no choice of treatment)
was explained at length, and eligibility criteria were
checked again. If after reading and hearing the informa-
tion and being allowed to ask additional questions
patients were still interested in participating, a visit for
inclusion and informed consent was scheduled as soon as
possible. Patients not included in the trial were allowed to
start their UVB therapy of choice without any further
delay.
Randomisation procedure
Every patient eligible for UVB phototherapy who was will-
ing to participate in the study was registered at the central
coordination centre. After providing informed consent
and registration of baseline data a randomisation number
corresponding with either home or outpatient photother-
apy was drawn from a computer-generated list. Randomi-
sation took place using stratified randomisation, in
particular the minimisation method described by Pocock
[19]. This method assigned the two treatments taking into
account the recruiting hospital and possible previous
experiences with UV phototherapy. After randomisation,
both patient and dermatologist were informed of the
assigned treatment, and this treatment was started accord-
ing to standard procedures.
UVB therapy and equipment
In the outpatient department
Patients randomised to the group treated in the outpatient
department received the UVB treatment in their own hos-
pital. The type of irradiation was restricted to narrowband
UVB (TL-01 tubes) [20]. All hospitals used their own treat-
ment schedules and their own (full circle) cabins. Some
types of cabins had UV indicators measuring irradiation
intensity (mW/cm2); others did not and measured only
treatment time. For cabins with intensity indicators, treat-
ment schedules were formulated in dosage (J/cm2). For
cabins without intensity indicators, treatments were pre-
scribed in units of time (seconds). Neither equipment nor
schedules were modified for the trial. The frequency of
irradiation was 2–3 times a week, depending on the hos-
pital.
At home
When patients were assigned to have home UVB photo-
therapy, the investigator placed an order with one of the
two home care organisations that provide the vast major-
ity of home UV phototherapy in the Netherlands [14].
Orders were divided equally between the two organisa-
tions, taking into account equal distributions per hospital
and the preferences of the patient's insurance company
(reimbursement). The UVB treatment was administered
in the patient's home, using equipment provided by one
of the home care organisations. The home phototherapy
units used were Waldmann UV-100 units with TL-01
lamps. This device comprises a semi-circular arrangement
of lamps. These units do not have an irradiation intensity
indicator; therefore treatments were prescribed in units of
time. The patients were instructed and supervised in the
use of the equipment by the nursing staff of the home care
institutions. The treatment schedules were the schedules
normally used by those institutions. Neither equipment
nor schedules were modified for the trial. The frequency
of irradiation was at least 3–4 times a week (i.e. once every
2 days, sometimes starting daily).
In general
In all cases the initial treatment plan was narrowband
UVB phototherapy according to randomisation. No pre-
specified treatment regimen was imposed on the partici-
pants and adjuvant use of topical therapy was allowed to
continue throughout the trial.
No other additional treatments or changes to the original
treatment plan were intended. However, in order to com-
pare the two UVB treatments under practical conditions
and to reflect clinical reality, alterations to the initial treat-
ment plan were allowed if the dermatologist decided they
were necessary. As such, all treatment changes originating
after inclusion and randomisation were permitted. For
instance, starting any type of medication after inclusion,BMC Medical Research Methodology 2006, 6:39 http://www.biomedcentral.com/1471-2288/6/39
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even systemic medication, was not considered a reason for
exclusion if the dermatologist considered this treatment
change necessary. Also, temporarily starting outpatient
phototherapy while waiting for placement of a home pho-
totherapy unit was allowed.
Outcome assessment
To answer the separate research questions, several out-
come assessments had to be performed during the trial.
The majority of the outcomes were measured using ques-
tionnaires or were assessed by an independent, blinded
research nurse.
Effectiveness
We assessed the effectiveness of both treatments using the
Psoriasis Area and Severity Index (PASI) [21] and the Self-
Administered PASI (SAPASI) [22]. Both indices evaluate
the severity of the psoriatic lesions ànd the area of psori-
atic involvement. Their scores vary from 0.0 (no lesions at
all) to 72.0 (complete erythroderma of the severest possi-
ble degree) [21]. An independent and blinded research
nurse administered the PASI during several patient visits
to the outpatient clinic. The SAPASI was easier to collect
using a questionnaire and was used as an equivalent of the
PASI as well as an indicator of the patient's own impres-
sion of the extent of the psoriasis lesions [22,23] Both the
PASI and the SAPASI were assessed for the whole body,
including the lower legs and the scalp. We also deter-
mined skin type according to Fitzpatrick's classification of
skin phototypes [24,25] and collected data on concomi-
tant use of medication, side effects, demographics and
past medical history.
Dosimetry
We routinely measured the light intensity (J/cm2) of all
UVB equipment from the hospitals with a small portable
Waldmann UV meter, type 585 100 (Villingen, Schwen-
ningen, Germany), referred to as meter A. If the cabin had
an irradiation intensity indicator, we compared its reading
with our own measurements. To collect information
about calculated treatment doses (mW/cm2), we made
copies of the treatment charts of the participants treated in
the outpatient departments.
The home care organisations measured the light intensity
of every unit before the first irradiation and after the last
irradiation, using their own small Waldmann UV meters,
all type 585 100, referred to as meters B. At the end of the
trial we collected these measurements and compared their
meters (B) with our own Waldmann UV-meter (A), cali-
brated with the High Accuracy UV-Visible Spectroradiom-
eter, type OL 752 (Orlando, Florida, U.S.A.).
Both groups of participants kept a record of their treat-
ment times in their diary. For all patients we calculated
standardised cumulative doses using the intensity meas-
urements together with the individual treatment charts
and/or diaries. The way cumulative doses were standard-
ised in this trial is described in table 2.
Quality of life (QoL)
To assess quality of life we used one disease-specific ques-
tionnaire and several universal questionnaires. The stand-
ard questionnaires that were used were:
￿ Psoriasis Disability Index (PDI) [26,27]
￿ Short Form-36 (SF-36) [28,29], and
￿ EuroQol (EQ-5D) [30,31]
The PDI is a short questionnaire consisting of 15 ques-
tions regarding disability due to psoriasis. Answers are
recorded on a seven point linear scale where '1' indicates
no disability and '7' indicates maximum disability. There-
fore the maximum potential PDI score is 105, with a min-
imum of 15 [27]. One of the generic QoL questionnaires
used in the study is the SF-36, a 36-item questionnaire
yielding a profile of 8 dimensions. All dimensions range
in score from 0 to 100, with higher scores indicating a
higher level of health status. By adding weighted combi-
nations, the 8 scales can be combined into a physical and
a mental component summary score. The EQ-5D is also a
generic quality of life questionnaire. It was developed to
assess the impact of a disease in terms of multi-attribute
value judgements yielding one overall value judgement, a
so-called utility score ranging between 0 (dead) and 1
(optimal health) [30,31]. When utility scores are plotted
against time, the Area Under the Curve (AUC) reflects the
Quality Adjusted Life time usually expressed in Years
(QALY's). Thus QALY's will be calculated as follows: util-
ity scores from two timepoints will be linearly interpo-
lated (i.e. summed and devided by two). This outcome
will be multiplied by the time difference. This procedure
will be repeated for all parts of the curve, and the out-
comes of all parts of the curve will be summed and ulti-
mately yield an estimate of the entire AUC. In this way
QALY's will be calculated for all patients, and a mean and
standard error of the mean (SEM) will be determined.
Besides these standard questionnaires, we designed a brief
"Burden of treatment" (BOT) questionnaire with 4 ques-
tions on the perceived burden of the UVB treatment (espe-
cially the specific burden of the treatment method and the
burden of the time lost to treatment), and we developed a
questionnaire on patient satisfaction. The patient satisfac-
tion questionnaire asked about:
￿ waiting times,BMC Medical Research Methodology 2006, 6:39 http://www.biomedcentral.com/1471-2288/6/39
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￿ perceived improvement of the psoriasis lesions,
￿ satisfaction with the treatment as a whole,
￿ satisfaction with the final treatment result,
￿ satisfaction with the rate of improvement,
￿ satisfaction with the nurses' supervision,
￿ perceived extent of side effects,
￿ perceived safety of the treatment,
￿ perceived advantages and drawbacks of both modes of
therapy, and
￿ preferences with regard to future UVB treatment, if nec-
essary (home UVB phototherapy versus UVB treatment in
the hospital).
Costs
Estimation of costs will be based partially on the actual
cost of the resources used, for instance the rental price of
home UVB light panels, the cost of using hospital equip-
ment, and travel expenses among others. Some indirect
costs-such as the loss of work time due to decreased effi-
ciency or absenteeism-were assessed using the "Health
and Labour Questionnaire" [32], a general introductory
questionnaire and the previously mentioned diary. These
two questionnaires will supply information on time lost
or expenses incurred for the treatment of the psoriasis, for
instance the cost of transportation to a dermatologist or
general practitioner. The diary on the other hand provides
information on the frequency of these types of expenses
during the treatment period. From the patients' pharma-
cists we obtained data on the use of medications and their
prices. The friction cost method [33] will be applied to
assess the losses to society due to sick leave.
Cost-effectiveness
A direct comparison will be made between the effective-
ness of the two therapeutic modalities and their associ-
ated cost. Incremental cost per additional patient treated
successfully and costs per QALY gained will be estimated.
Cost-effectiveness (CE) will be calculated for a time hori-
zon of 12 (11–13) months after randomisation/inclusion.
The quality of life (QoL) questionnaires were no longer
administered after cessation of irradiation. Based on the
association between clinical symptoms and QoL, the
impact in terms of QoL for the remaining follow-up, i.e.
up to 12 months, will be extrapolated using regression
models. Subsequently, cost per QALY can be calculated. In
case the difference in effectiveness is less than 15%, we
will consider this as equal effectiveness and will limit the
economic evaluation to a cost minimisation analysis.
Table 2: Calculation of standardised cumulative doses for the three different situations in the trial.
Situation Treatment location UVB equipment Treatment schedule Cumulative Dose (CD) Standardisation 
factor F
1 In the hospital With intensity indicator in J/cm2 CD = CDh × F
2 In the hospital Without intensity indicator in time (seconds) CD = CTT × IA × F
3 At home Without intensity indicator in time (seconds)
CD = Cumulative Dose (J/cm2) standardised for the study.
CDh = Cumulative Dose (J/cm2) as calculated by the hospital (retrieved from treatment chart).
CTT = Cumulative Treatment Time (s) as retreived from the diary and/or treatment chart.
F = correction factor for standardisation.
Measurements on location:
IA = Intensity (mW/cm2) as measured by the investigators for each hospital UVB unit with portable intensity meter A.
Ih = Intensity (mW/cm2) as simultaneously measured by the hospitals' UVB unit irradiation intensity indicator.
IB1 = Intensity (mW/cm2) measured by the home care organisations before start of first treatment, using their meters (B).
IB2 = Intensity (mW/cm2) measured by the home care organisations after finishing last treatment, using their meters (B).
Measurements during calibration:
IcA = Intensity (mW/cm2) as measured during calibration by the investigators' portable intensity meter A.
IcB = Intensity (mW/cm2) as measured during calibration by the intensity meters (B) of the home care organisations.
Isr = Intensity (mW/cm2) as measured during calibration with the High Accuracy Spectroradiometer type OL 752
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Measurement planning
Outcome measurement was planned according to time
points specified in the timetable in figure 1. Briefly, the
procedure was as follows: When patients were willing to
participate, we arranged a visit with an independent
research nurse. During this visit, patients signed a consent
form, baseline data were recorded and instructions were
given on the use of the diary and questionnaires.
Immediately after this first visit, patients were randomised
using the baseline data (information on the recruiting
hospital and any previous experience of the patient with
UV therapy were used to determine the randomisation
strata). Both patient and attending dermatologist were
informed about the type of treatment assigned, and the
treatment was started accordingly. When (sometimes after
a waiting period) the therapy was started, the patients did
Timetable Figure 1
Timetable. Schematic representation of successive time points for data collection, reported for all outcome measures and 
questionnaires.
* 23 irradiations: outcome measurement was planned at approximately 23 irradiations, with a minimum of 20 and a maximum 
of 26 irradiations.
** End of therapy: measurement was planned at the end of the treatment. When more than 46 irradiations were needed, 
measurement was planned at 46 irradiations.
*** Follow-up: Starting at the end of the therapy (or at the 46th irradiation, see **), follow-up measurements were planned 
every 2 months, for up to 1 year after the last irradiation.BMC Medical Research Methodology 2006, 6:39 http://www.biomedcentral.com/1471-2288/6/39
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a SAPASI-assessment and began using the study diary. At
approximately 23 (20–26) UVB treatments ànd at the end
of the therapy (or 46 treatments) the patients received a
series of questionnaires at home. Visits to the previously
mentioned research nurse were scheduled for the same
time points. Throughout the whole trial, the independent
research nurse was not informed about the randomisation
results and therefore remained blinded.
For all UVB therapies lasting longer than 46 treatments, a
cutoff point of maximally 46 treatments was used to
establish effectiveness. The choice of 46 as the maximum
number of treatments was derived from unpublished data
from the home care organisations about the treatment
duration of their patients.
At the end of the therapy (or 46 treatments), 105 patients
were followed for 12 more months to monitor long term
effectiveness and cost. The patients received a short ques-
tionnaire at home every 2 months and returned this ques-
tionnaire by mail. At the end of the follow-up,
information on medication use during the trial period
was retrieved retrospectively for each patient from his/her
pharmacist.
Ethics & informed consent
The final protocol was approved by the Medical Ethics
Committees of all participating hospitals. Patients were
able to quit the study at any time. Informed consent was
obtained after the study objectives, types of therapy, ben-
efits and risks, and the concept of randomisation had
been explained extensively. The study was performed
according to the principles of Good Clinical Practice [34].
Statistical analysis
All data will be analysed according to the intention to
treat principle, meaning all included patients will be ana-
lysed according to the group they were randomised to.
This includes patients who dropped out or changed ther-
apy. The statistical methods that will be used are chosen
in accordance with the type of data that is available. For
continuous data differences and their 95% Confidence
Intervals (95% CIs) will be presented. In case of binary
outcomes, differences in proportion with 95% CIs will be
calculated. Whether randomisation was successful will be
determined by assessing comparability of baseline charac-
teristics. No formal statistical tests are foreseen. In the
event apparent differences are noted, a multivariate anal-
ysis will be performed to adjust for potential confound-
ing.
Effectiveness
Assessment of effectiveness of both UVB treatments will
take place through calculation of the PASI and SAPASI-
scores for both treatment modalities at regular points in
time, and subsequently calculating differences in
(SA)PASI scores over time. Possible differences in effec-
tiveness between the two therapies will be established
through comparison of differences in (SA)PASI scores
inclusive of 95% CIs. The side effects of the therapy were
reported for each irradiation as being present ("yes") or
not being present ("no"). For each type of side effect the
answers will be compared on a group level and presented
with their 95% CIs.
Dosimetry
Cumulative dosimetry will be determined as formulated
above in table 2. Comparison of cumulative doses
between the treatment groups will be done by calculating
the difference in mean dose with its 95% CI.
Quality of life (QoL)
Continuous sum-scores of the QoL questionnaires will be
compared by calculating differences in QoL and their 95%
CIs. Changes in QoL will also be compared across groups.
Costs
Both costs as reimbursed by the health insurance compa-
nies and actual costs as calculated by including all
expenses (direct and indirect) will be compared for the
two treatments as difference in cost with a 95% CI. The
uncertainty associated with the point estimates will be
evaluated using bootstrapping [35].
Cost-effectiveness
Initially the trial estimate of the incremental cost per addi-
tional patient with successful outcome will be assessed.
Similarly, the cost per QALY gained will be estimated. To
assess uncertainty with regard to incremental cost-effec-
tiveness a standard bootstrap technique will be applied
[35]. The trial data will be randomly sampled with
replacement from the original dataset 1000 times. For
each bootstrap sample the incremental costs and effects
will be calculated and plotted (costs on the y-axis and
effects on the x-axis). Thus an integrated presentation of
the mutually dependent cost and effect differences is
obtained that may be interpreted as a direct reflection of
the uncertainty, i.e. a two dimensial dispersion, with
regard to the incremental cost-effectiveness ratio. Using
this so-called CEA Plane (Cost-effectiveness Analysis
Plane), an inference regarding the likelihood of one treat-
ment being more cost-effective than the other can be
made [36].
Other data
These include concomitant use of medication, data on
patient satisfaction and on the burden of both treatments.
These data will also be compared across groups and be
presented as differences with 95% CIs.BMC Medical Research Methodology 2006, 6:39 http://www.biomedcentral.com/1471-2288/6/39
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Results
Recruitment of patients was stopped after 2 years and 2 1/
2 months. Initially 252 possible participants were
recruited by the participating hospitals. Of these 252
patients, 56 were excluded from starting the trial for a vari-
ety of reasons. Thirty-three (33) patients had a clear pref-
erence for either home or hospital-based therapy and
refused to submit to being randomised. Another 11
patients did not want to participate in a study, 6 patients
did not fulfill the inclusion criteria or met one of the
exclusion criteria, 2 had already started UVB therapy, 2
persons decided not to be treated with UVB, and 2
patients were excluded for other practical reasons.
Thus, in total 196 patients (252–56) were included in the
study. A consecutive sample of 105 patients was followed
for 12 months after the end of the treatment in order to
gain sufficient data about the costs incurred after the treat-
ment. Randomisation according to the minimisation
method [19] was successful. The two factors accounted
for, their levels and the number of assigned therapies are
shown in table 3.
The therapy took place according to randomisation for
184 patients. Five (5) patients switched therapy (protocol
violators), of which four patients switched to home UVB
phototherapy. Another seven (7) patients never started
therapy. Of those seven patients, four (4) had their lesions
improve during the waiting period before treatment could
be started and did not need UVB treatment after all (three
of them were randomised to the group receiving home
UVB treatment). The other three (3) that did not receive
therapy withdrew respectively because of agoraphobia,
not wanting to participate in the study, and not wanting
any treatment during pregnancy. Two of them were
assigned to have outpatient phototherapy.
Discussion
This article presents the design of the first randomised
controlled trial of home UVB phototherapy for psoriasis.
The design of this trial was 'pragmatic', which means that
we did not adapt daily practice to conform to a specific
protocol: the two treatments were compared under the
conditions in which they would be applied in daily prac-
tice [15]. In contrast to a pragmatic trial, an 'explanatory'
trial studies treatments under controlled idealised or
equalised conditions, preferably by means of a double-
blind placebo-controlled study design and a rigid research
protocol [15]. Thus, explanatory trials aim at providing
information on the effects of a single difference in treat-
ment, while a pragmatic trial compares two treatment
strategies as a whole [15]. Consequently, in a pragmatic
trial the treatments will be carried out just as they would
have been without the trial, and therefore the advantage
of a pragmatic design is the assurance that the results can
easily be generalised to the target population. As a result,
this trial will make a valuable and important contribution
to the evidence base for the use of home UVB photother-
apy for patients with psoriasis. It will produce a solid esti-
mate of the effectiveness of home UVB treatment
compared to UVB phototherapy in an outpatient setting.
Of the five previously conducted studies on home UVB
treatment, only two compare two groups of patients [14].
Table 3: Results of the randomisation procedure.
Number of patients
Factor Level Hospital Home Total
Hospital UMC Utrecht 24 25 49
Hilversum Hospital 14 15 29
Academic Hospital Maastricht 9 9 18
Diakonessen Hospital Utrecht 9 8 17
Meander Hospital Amersfoort 7 8 15
Groene Hart Hospital Gouda 6 5 11
AMC Amsterdam 5 5 10
Erasmus MC Rotterdam 5 4 9
VUmc Amsterdam 4 5 9
Gelre Hospital Apeldoorn 5 3 8
Diakonessen Hospital Zeist 3 4 7
Reinier de Graaf Hospital Delft/Voorburg 4 3 7
AntoniusMesosGroup Hospitals Nieuwegein/Utrecht 2 2 4
Lucas Andreas Hospital Amsterdam 1 2 3
Previous UV phototherapy Yes 50 50 100
No 48 48 96
Stratified randomisation, in particular the minimisation method described by Pocock [19] was used, which took into account (1) the recruiting 
hospital, and (2) possible previous experience of the patient with UV therapy. This table shows the results of the treatment assignment by the two 
factors for 196 patients.BMC Medical Research Methodology 2006, 6:39 http://www.biomedcentral.com/1471-2288/6/39
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Our study addresses two weaknesses encountered in those
earlier studies. First of all, our trial has a parallel group
design in order to compare the two treatments during the
same seasons of the year. Secondly, to obtain two similar
groups of patients and thus prevent selection bias, assign-
ment of treatments is by randomisation. As such, this
study is the first to perform a parallel group randomised
comparison of home UVB phototherapy with UVB treat-
ment in an outpatient setting.
Another strength of the study is that it is designed to com-
pare the two treatments as they are carried out in daily
practise (pragmatic design), guaranteeing a good general-
isability of the results. A further substantial difference
with other trials in this field is that in addition to the effec-
tiveness of the two therapies, the impact of each treatment
on quality of life and on its associated costs is assessed. A
cost-effectiveness analysis will be conducted to investigate
the aspects of expense and effectiveness together. The trial
will also provide information about patient satisfaction,
travel time, side effects, cumulative dosimetry, concomi-
tant use of medication, waiting periods and total treat-
ment duration. The manner in which data collection was
planned throughout the trial ensures that both groups can
be compared during the treatment period without impor-
tant differences in the number of irradiations. During the
follow-up the measurements are all comparable with
regard to the time interval since the last irradiation.
There are however also some weak points which bear dis-
cussion. For instance, because the measurement planning
does not use fixed time points starting from inclusion, for
most patients the outcome at 12 months after inclusion
(used to calculate cost-effectiveness) will have to be inter-
polated from the two adjacent measurements. These two
adjacent measurements are only two months apart, thus
providing a solid basis for interpolation. Also, the EQ-5D
questionnaire was only administered until the end of the
treatment and not during the remaining follow-up period,
making direct calculation of QALY's for this period impos-
sible. We will have to rely on extrapolation from the treat-
ment period. Another issue for discussion is that during
the trial it was impossible to keep a record of all patients
with psoriasis who were prescribed TL-01 UVB treatment
but who were nòt referred to the central coordination cen-
tre. We therefore do not know the reasons for non-referral.
Overall, we feel that this trial has many benefits and will
prove to be a very valuable addition to the current litera-
ture in the field. It is the first trial to compare these two
commonly used treatments directly in a randomised par-
allel group design. Moreover, the study design allows for
more than one objective. Besides clinical effectiveness, it
also evaluates quality of life and cost-effectiveness. Being
a pragmatic trial, it will be easy to generalise the results of
this study to the target population. With 196 participants,
the study is adequately powered to detect a 15% reduction
in effectiveness, and the other outcome parameters can
also be determined adequately. The results of this study
will be available in 2006.
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